Psyence Biomedical (PBM) Receivables (2023 - 2024)
Psyence Biomedical (PBM) posted Receivables of $186657.8 for Q1 2024, down 37.55% on a QoQ basis from $298898.6 in Q1 2023, and down 37.55% year-over-year from $298898.6 in Q2 2023.
Powered by 
Analysis
Psyence Biomedical (PBM) Receivables (2023 - 2024) Analysis & Trends
Psyence Biomedical has reported Receivables for 2 years, with the latest figure at $186657.8 in Q1 2024.
- On a quarterly basis, Receivables fell 37.55% year-over-year to $186657.8 in Q1 2024; TTM through Mar 2024 was $186657.8, a 37.55% decrease from a year earlier, with the FY2024 full-year figure at $186657.8, down 33.32% from the prior year.
- Receivables was $186657.8 for Q1 2024 at Psyence Biomedical, down from $298898.6 in the prior quarter.
- The five-year high for Receivables was $298898.6 in Q1 2023, with the low at $186657.8 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.34 Bn | 192.35 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 131.22 Bn | 123.37 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.84 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 54.18 Bn | 49.05 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.22 Bn | 29.91 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 29.06 Bn | 29.06 Bn | 1.16 Mn | - |
| 10 | Psyence Biomedical | 2.73 Mn | 2.73 Mn | - | - |